Received May 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 2345b | LA |
The first dose had been given on February 7, 2025, and the second dose had been given on May 9, 2025, six months earlier; This non-serious case was reported by a other health professional via sales rep and described the occurrence of drug dose administration interval too short in a 54-year-old male patient who received HAV (Havrix adult) (batch number 2345b, expiry date 02-FEB-2026) for prophylaxis. Concurrent medical conditions included fatty liver, hypertension and sleep disorder. Concomitant products included Hepatitis a vaccine inact (Havrix) and amitriptyline. On 09-MAY-2025, the patient received Havrix adult (left deltoid). On 09-MAY-2025, an unknown time after receiving Havrix adult, the patient experienced drug dose administration interval too short (Verbatim: The first dose had been given on February 7, 2025, and the second dose had been given on May 9, 2025, six months earlier). The outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 09-MAY-2025 The first dose had been given on 7th February 2025, and the second dose had been given on 9th May 2025, six months earlier, which led to Drug dose administration interval too short. No symptoms had been recorded.
Fatty liver; Hypertension; Sleep disorder
Havrix; Amitriptyline